SU11274

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：SU11274	Purity：98% min
CAS NO：658084-23-2	Solubility：DMSO : ≥ 100 mg/mL (176.03 mM)
Molecular Formula：C₂₈H₃₀ClN₅O₄S	Package：Package according to customer requirements
Molecular Weight：568.087	Storage：Store at -20℃

Quality control

Remarks

SU11274 is a selective Met tyrosine kinase inhibitor with IC50 of 10 nM. SU11274 increases tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation. SU11274 suppresses proliferation and motility of pancreatic cancer cells. SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation. SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.

Related Products:

MGCD-265 analog; BMS777607; JNJ-38877605; Tivantinib; AMG-208; AMG-458; NVP-BVU972; Golvatinib; BMS-794833; PF-04217903; Crizotinib

References

[1]. Wang X, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther, 2003, 2(11):1085-1092.

[2]. Sattler M, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res, 2003, 63(17), 5462-5469.